Medicines for older people

The European Medicines Agency (EMA) plays an important role in ensuring that the needs of older people are taken into account in the development, approval and use of medicines in the European Union. This includes developing guidelines on how to address the specific requirements of older patients in medicine development programmes and improving the provision of information for those patients.

Older people are the fastest growing population group in Europe and are the main users of medicines.

EMA has been undertaking various initiatives to ensure that the development, evaluation and safety monitoring of medicines take into account the unique considerations associated with older patients.

Geriatric medicines strategy

EMA's geriatric medicines strategy sets out the Agency's vision for better addressing the needs of older people in the development and evaluation of medicines, by building on its existing activities:

The strategy aims to:

  • ensure that the medicines used by older people are of high quality and are studied appropriately in the older population, throughout the medicinal product lifecycle;
  • improve the availability of information for older people on the use of medicines.

EMA published the strategy in 2011.

EMA has also set up a Geriatric Expert Group to advise the Agency and its Committee for Medicinal Products for Human Use (CHMP) on issues related to the elderly and to provide scientific advice to medicine developers.

Call for geriatric experts (new)

New: EMA is inviting clinicians, experts and patient representatives specialised in geriatrics to express interest in supporting the work of EMA and its scientific committees.

EMA will call on selected geriatric experts to provide supplementary expertise when needed, such as independent scientific or technical recommendations related to medicines under evaluation and helping develop position papers or guidance documents.

Interested candidates should apply by 30 September 2023 using the link below: 

As this application involves several administrative steps, before proceeding please carefully consider whether you fulfill the essential selection criteria listed below: 

GroupEssential criteria
All candidatesIndependence, impartiality, objectivity and absence of conflicts of interest as outlined in the PDF icon EMA policy on the handling of competing interests of scientific committees’ members and experts
 Fluency in English, the working language of EMA
Clinicians and expertsPublications in major journals or relevant clinical work in disciplines such as nursing, polypharmacy and oncology
Patient representativesAbility to contribute real-life experiences of old people living with related health conditions, as well as the management of these conditions and use of medicines to complement the scientific evidence available to EMA

Desirable criteria:

  • experience in contributing to national competent authority or EMA assessment activities;
  • membership of a recognised multinational geriatric-focused learned society.

EMA will include all candidates who meet the essential criteria in its public list of European experts. The desirable criteria will help EMA identify which experts may contribute in different areas.

    Expenses covering accommodation, travel and a daily allowance will be paid in line with PDF icon EMA’s reimbursement rules .

    Selected experts will not be remunerated for this work. They will usually need to invest four to six hours of their time on each activity. 

    Support for medicine development

    Scientific guidelines are available to help medicine developers address the specific requirements of older people in their medicine development programmes, including in the design and conduct of clinical trials:

    In addition, EMA encourages medicine developers to address questions on developing medicines for use in the older population as part of scientific advice or in business-pipeline meetings.

    EMA also aims to ensure that all of its scientific guidelines relevant for older patient populations take account of the needs of those patients. In 2013, the Agency published an analysis of the number of scientific guidelines that it reviewed and provided comments on to reflect the geriatric population between 2011 and 2013:

    In 2006, EMA published a report on the extent to which CHMP guidelines and clinical trials supporting marketing authorisations address the needs of older people. This found adequate compliance with international requirements and made recommendations on how to improve the implementation of existing guidelines and update guidelines on the design and conduct of clinical trials:

    Improving product information

    With the aim of improving product information and enabling informed prescription, EMA's CHMP has revised its assessment templates and guidance to assessors to improve clarity of geriatrics-specific issues. This should help:

    The CHMP first updated the assessment template with clearer information on the number of elderly people involved in a medicine's clinical-trial programme and side effects in older patients in 2011.

    It ran a pilot on a dedicated geriatric section in the Day 80 and Day 210 assessment templates with ten new medicines between May 2016 and March 2018. The CHMP will decide on inclusion of updates in the standard templates following an assessment of the pilot.

    EMA has also prepared training on how to reflect information targeted at older patients in the summary of products characteristics:

    In 2013, EMA published an analysis on how appropriately product information reflected data on the geriatric population in marketing authorisation applications submitted between 2011 and 2013:


    When evaluating marketing authorisation applications, EMA's CHMP considers if specific activities concerning aspects such as co-morbidities and the monitoring of specific side effects associated with older patients should be included in the risk management plan or as post-authorisation measures.

    EMA is also developing a specific module of the guideline on good pharmacovigilance practices (GVP) which will address the specific needs of the geriatric population. 

    Stakeholder meetings


    How useful was this page?

    Add your rating
    4 ratings
    1 rating
    1 rating
    1 rating